Page 1 | Search Results | Cancer Immunology Research | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer

Cancer Immunol Res (2021) 9 (7): 790–810.

https://doi.org/10.1158/2326-6066.CIR-20-0922

Published: 01 July 2021

View article titled, Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer

Includes: Supplementary data

Journal Articles

Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils

ANM Nazmul H. Khan, Tiffany R. Emmons, Jerry T. Wong, Emad Alqassim, Kelly L. Singel, Jaron Mark, Brandon E. Smith, Joseph D. Tario, Kevin H. Eng, Kirsten B. Moysich, Kunle Odunsi, Scott I. Abrams, Brahm H. Segal

Cancer Immunol Res (2020) 8 (6): 819–828.

https://doi.org/10.1158/2326-6066.CIR-19-0556

Published: 01 June 2020

View article titled, Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils

Includes: Supplementary data

Journal Articles

Abstract B36: TGFβ blockade and epigenetic modulation for cancer treatment: Efficient breast cancer targeted therapy with TCR-T cell transfer

Satoko Matsueda, Kunle Odunsi, Richard C. Koya

Cancer Immunol Res (2020) 8 (4_Supplement): B36.

https://doi.org/10.1158/2326-6074.TUMIMM18-B36

Published: 01 April 2020

View article titled, Abstract B36: TGFβ blockade and epigenetic modulation for cancer treatment: Efficient breast cancer targeted therapy with TCR-T cell transfer

Journal Articles

Abstract A022: Phase 1/2 study to evaluate systemic durvalumab (durva) + intraperitoneal ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC)

Dmitriy Zamarin, Kunle Odunsi, Brian Slomovitz, Vanessa M. Hubbard-Lucey, Danielle McCabe, Lisa Shohara, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Anne-Kirsti Aksnes, Lukasz Kuryk, Ralph Venhaus

Cancer Immunol Res (2019) 7 (2_Supplement): A022.

https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-A022

Published: 01 February 2019

View article titled, Abstract A022: Phase 1/2 study to evaluate systemic durvalumab (durva) + intraperitoneal ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC)

Journal Articles

Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors

Margaret K. Callahan, Kunle Odunsi, Mario Sznol, John Nemunaitis, Patrick A. Ott, Patrick Dillon, Reva Schneider, Andrew Park, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus, Jedd D. Wolchok

Cancer Immunol Res (2019) 7 (2_Supplement): A006.

https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-A006

Published: 01 February 2019

View article titled, Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors

Journal Articles

Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy

Takemasa Tsuji, Akira Yoneda, Junko Matsuzaki, Anthony Miliotto, Courtney Ryan, Richard C. Koya, Kunle Odunsi

Cancer Immunol Res (2018) 6 (5): 594–604.

https://doi.org/10.1158/2326-6066.CIR-17-0434

Published: 30 April 2018

View article titled, Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy

Includes: Supplementary data

Journal Articles

Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses

Gautam N. Shenoy, Jenni Loyall, Orla Maguire, Vandana Iyer, Raymond J. Kelleher, Jr, Hans Minderman, Paul K. Wallace, Kunle Odunsi, Sathy V. Balu-Iyer, Richard B. Bankert

Cancer Immunol Res (2018) 6 (2): 236–247.

https://doi.org/10.1158/2326-6066.CIR-17-0113

Published: 31 January 2018

View article titled, Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses

Includes: Supplementary data

Journal Articles

Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment

Jeffrey L. Wong, Nataša Obermajer, Kunle Odunsi, Robert P. Edwards, Pawel Kalinski

Cancer Immunol Res (2016) 4 (4): 303–311.

https://doi.org/10.1158/2326-6066.CIR-15-0157

Published: 31 March 2016

View article titled, Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment

Includes: Supplementary data

Journal Articles

Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade

Raymond J. Kelleher, Jr, Sathy Balu-Iyer, Jenni Loyall, Anthony J. Sacca, Gautam N. Shenoy, Peng Peng, Vandana Iyer, Anas M. Fathallah, Charles S. Berenson, Paul K. Wallace, Joseph Tario, Kunle Odunsi, Richard B. Bankert

Cancer Immunol Res (2015) 3 (11): 1269–1278.

https://doi.org/10.1158/2326-6066.CIR-15-0086

Published: 04 November 2015

View article titled, Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade

Includes: Supplementary data

Journal Articles

Nonclassical Antigen-Processing Pathways Are Required for MHC Class II–Restricted Direct Tumor Recognition by NY-ESO-1–Specific CD4⁺ T Cells

Junko Matsuzaki, Takemasa Tsuji, Immanuel Luescher, Lloyd J. Old, Protul Shrikant, Sacha Gnjatic, Kunle Odunsi

Cancer Immunol Res (2014) 2 (4): 341–350.

https://doi.org/10.1158/2326-6066.CIR-13-0138

Published: 03 April 2014

View article titled, Nonclassical Antigen-Processing Pathways Are Required for MHC Class II–Restricted Direct Tumor Recognition by NY-ESO-1–Specific CD4<sup>+</sup> T Cells

Includes: Supplementary data

Journal Articles

Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome

Bridget Charbonneau, Kirsten B. Moysich, Kimberly R. Kalli, Ann L. Oberg, Robert A. Vierkant, Zachary C. Fogarty, Matthew S. Block, Matthew J. Maurer, Krista M. Goergen, Brooke L. Fridley, Julie M. Cunningham, David N. Rider, Claudia Preston, Lynn C. Hartmann, Kate Lawrenson, Chen Wang, Jonathan Tyrer, Honglin Song, Anna deFazio, Sharon E. Johnatty, Jennifer A. Doherty, Catherine M. Phelan, Thomas A. Sellers, Starr M. Ramirez, Allison F. Vitonis, Kathryn L. Terry, David Van Den Berg, Malcolm C. Pike, Anna H. Wu, Andrew Berchuck, Aleksandra Gentry-Maharaj, Susan J. Ramus, Brenda Diergaarde, Howard Shen, Allan Jensen, Janusz Menkiszak, Cezary Cybulski, Jan Lubiński, Argyrios Ziogas, Joseph H. Rothstein, Valerie McGuire, Weiva Sieh, Jenny Lester, Christine Walsh, Ignace Vergote, Sandrina Lambrechts, Evelyn Despierre, Montserrat Garcia-Closas, Hannah Yang, Louise A. Brinton, Beata Spiewankiewicz, Iwona K. Rzepecka, Agnieszka Dansonka-Mieszkowska, Petra Seibold, Anja Rudolph, Lisa E. Paddock, Irene Orlow, Lene Lundvall, Sara H. Olson, Claus K. Hogdall, Ira Schwaab, Andreas du Bois, Philipp Harter, James M. Flanagan, Robert Brown, James Paul, Arif B. Ekici, Matthias W. Beckmann, Alexander Hein, Diana Eccles, Galina Lurie, Laura E. Hays, Yukie T. Bean, Tanja Pejovic, Marc T. Goodman, Ian Campbell, Peter A. Fasching, Gottfried Konecny, Stanley B. Kaye, Florian Heitz, Estrid Hogdall, Elisa V. Bandera, Jenny Chang-Claude, Jolanta Kupryjanczyk, Nicolas Wentzensen, Diether Lambrechts, Beth Y. Karlan, Alice S. Whittemore, Hoda Anton Culver, Jacek Gronwald, Douglas A. Levine, Susanne K. Kjaer, Usha Menon, Joellen M. Schildkraut, Celeste Leigh Pearce, Daniel W. Cramer, Mary Anne Rossing, Georgia Chenevix-Trench, for the AOCS group, ACS, Paul D.P. Pharoah, Simon A. Gayther, Roberta B. Ness, Kunle Odunsi, Lara E. Sucheston, Keith L. Knutson, Ellen L. Goode

Cancer Immunol Res (2014) 2 (4): 332–340.

https://doi.org/10.1158/2326-6066.CIR-13-0136

Published: 03 April 2014

View article titled, Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome

Includes: Supplementary data

Journal Articles

Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

Kunle Odunsi, Junko Matsuzaki, Smitha R. James, Paulette Mhawech-Fauceglia, Takemasa Tsuji, Austin Miller, Wa Zhang, Stacey N. Akers, Elizabeth A. Griffiths, Anthony Miliotto, Amy Beck, Carl A. Batt, Gerd Ritter, Shashikant Lele, Sacha Gnjatic, Adam R. Karpf

Cancer Immunol Res (2014) 2 (1): 37–49.

https://doi.org/10.1158/2326-6066.CIR-13-0126

Published: 02 January 2014

View article titled, Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

Includes: Supplementary data

Journal Articles

CD4⁺ T Effectors Specific for the Tumor Antigen NY-ESO-1 Are Highly Enriched at Ovarian Cancer Sites and Coexist with, but Are Distinct from, Tumor-Associated Treg

Maha Ayyoub, Pascale Pignon, Jean-Marc Classe, Kunle Odunsi, Danila Valmori

Cancer Immunol Res (2013) 1 (5): 303–308.

https://doi.org/10.1158/2326-6066.CIR-13-0062-T

Published: 01 November 2013

View article titled, CD4<sup>+</sup> T Effectors Specific for the Tumor Antigen NY-ESO-1 Are Highly Enriched at Ovarian Cancer Sites and Coexist with, but Are Distinct from, Tumor-Associated Treg

NARROW

Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer

Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils

Abstract B36: TGFβ blockade and epigenetic modulation for cancer treatment: Efficient breast cancer targeted therapy with TCR-T cell transfer

Abstract A022: Phase 1/2 study to evaluate systemic durvalumab (durva) + intraperitoneal ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC)

Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors

Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy

Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses

Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment

Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade

Nonclassical Antigen-Processing Pathways Are Required for MHC Class II–Restricted Direct Tumor Recognition by NY-ESO-1–Specific CD4⁺ T Cells

Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome

Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

CD4⁺ T Effectors Specific for the Tumor Antigen NY-ESO-1 Are Highly Enriched at Ovarian Cancer Sites and Coexist with, but Are Distinct from, Tumor-Associated Treg

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only